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Background: Merkel cell polyomavirus (MCPyV), human polyomavirus-6 (HPyV6), and human polyomavirus-7
(HPyV7) were identified as viruses shed from the skin. Serological analysis revealed that these viruses are common
among the general population. However, there is little information about the presence of MCPyV, HPyV6, and
HPyV7 in the sera and tissues of immunocompromised individuals. The aims of this study are to know if immune
status affects the presence of MCPyV, HPyV6, and HPyV7 in the serum, and to reveal the presence of these viruses
in diseased tissues of unknown etiology.
Methods: Sera from HIV-1-positive and -negative patients were examined by real-time PCR and nested PCR
detecting MCPyV, HPyV6 and HPyV7. In addition, diseased tissue samples of unknown etiology were examined.
Results: Nine out of 23 serum samples (39.1%) from HIV-1-positive patients who had not received anti-retroviral
therapy were positive for MCPyV, which is significantly higher than HIV-1-negative patients (6/110, 5.5%, P < 0.01,
Chi-square test). MCPyV DNA was detected in tissue samples of Merkel cell carcinoma (22/30 [73%]), encephalitis
(4/19 [21%]), pneumonia (3/17 [18%]), and myocarditis (8/14 [57%]). With the exception of Merkel cell carcinoma
samples, MCPyV-positive tissues showed low copy numbers of MCPyV DNA by real-time PCR and no expression of
the MCPyV large T antigen by immunohistochemistry. HPyV6 and HPyV7 were rarely detected in serum and tissue
samples.
Conclusions: These results suggest that MCPyV viremia is associated with host immunity, and that circulation of
HPyV6 and HPyV7 in the serum is rare.
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Polyomavirus is a genus of non-enveloped viruses with
a circular double-stranded DNA genome of approxi-
mately 5 kb. To date, 9 polyomaviruses have been dis-
covered in humans: BK virus [1], JC virus [2], KI virus
[3], WU virus [4], Merkel cell polyomavirus (MCPyV)
[5], human polyomavirus-6 and 7 (HPyV6 and HPyV7)
[6], trichodysplasia spinulosa-associated polyomavirus
[7], and HPyV9 [8].
MCPyV is the fifth human polyomavirus. It was identi-
fied in a patient with Merkel cell carcinoma (MCC) by
using digital transcriptome subtraction [5]. MCC is a
rare but aggressive neuroendocrine skin tumor, with ap-
proximately 80% of cases positive for MCPyV [9-22].* Correspondence: katano@nih.go.jp
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distribution, and reproduction in any mediumSerological tests revealed that the majority of adults are
seropositive for MCPyV, with seroprevalence to the
MCPyV VP1 capsid protein ranging from 46% to 88%
in the general population, indicating high MCPyV preva-
lence among the general population [6,23-25]. A recent
study revealed the serological evidence of the MCPyV
primary infection in childhood [26]. MCPyV is detected
not only in MCC tissues but also in several tissues in-
cluding skin, oral cavity, liver, colon, lung, kidney, and
saliva of patients without MCC, suggesting MCPyV is
widespread in the human body [16,27]. In addition, a
very high detection rate (about 90%) was reported in
samples of environmental surfaces in contact with hu-
man skin by PCR, suggesting shedding of MCPyV from
the skin [28]. However, detail of virus titer in the blood
is unknown. It is reported that MCPyV DNA was not
detected by PCR in sera from 57 immunocompetenttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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(15%) of 20 immunosuppressed patients were positive
for MCPyV DNA in the serum [30].
In a recent study, HPyV6 and HPyV7 were isolated
from skin swabs of healthy donors by using rolling circle
amplification (RCA) [6]. The study suggests that infec-
tion by these viruses is common among the general
population, showing a seroprevalence of 69% for HPyV6
and 35% for HPyV7 in a cohort of 95 blood donors.
However, the presence of HPyV6 and HPyV7 DNA in
sera has not been reported. In addition, previous studies
have not found evidence for a strong association be-
tween HPyV6 or HPyV7 infection and any disease. For
example, 1 study detected HPyV6 and HPyV7 DNA in
only 14% and 2% of skin samples of patients with skin
cancer (n = 108), respectively [31]. Other studies were
unable to detect HPyV6 and HPyV7 in neuroendocrine
tumors (n = 50) and MCC samples (n = 28) [32,33].
MCC occurs more frequently in HIV-1-positive pa-
tients than in immunocompetent hosts [34-37]. A study
using nested PCR analysis showed that HIV-1-positive
men had MCPyV DNA in the skin of forehead more fre-
quently than HIV-1-negative healthy controls [38]. In
addition, reactivation of human polyomaviruses such as
KI polyomavirus and WU polyomavirus was demon-
strated in immunocompromised hosts [39]. However, lit-
tle information about the presence of MCPyV, HPyV6,
and HPyV7 in the sera of immunocompromised individ-
uals is available. Moreover, these viruses have not been
examined in samples of patients with diseases of un-
known etiology. In the present study, sera from HIV-1
-positive and -negative patients were examined by real-
time PCR and nested PCR to know if immune status af-
fects the presence of MCPyV, HPyV6, and HPyV7 in the
serum. In addition, diseased tissue samples of unknown
etiology were examined.
Results
Frequent detection of MCPyV in sera of HIV-1-positive
patients
MCPyV was detected in 9 of 23 HIV-1-positive sera
(39.1%) and 6 of 110 HIV-1-negative sera (5.5%) by real-
time PCR (Table 1). The positivity of MCPyV among HIV-
positive patients was significantly higher than that among
HIV-1-negative patients (P < 0.01, Chi-square test). In
MCPyV-positive sera, there was no significant difference
in MCPyV copy number between HIV-1-positive (mean =Table 1 MCPyV, HPyV6, and HPyV7 detection in serum
samples by real-time PCR
Patient n MCPyV HPyV6 HPyV7
HIV+ 23 9 (39.1%) 0 (0%) 0 (0%)
HIV- 110 6 (5.5%) 2 (1.8%) 0 (0%)26.5 copies per μL) and HIV-1-negative patients (mean =
45.1 copies per μL, P = 0.09, Mann-Whitney U-test)
(Figure 1). Six MCPyV-positive sera in HIV-1-negative pa-
tients were two from congenital immunodeficiency pa-
tients, one from a sudden death patient with unknown
etiology, and three from myocarditis patients. Dot blots
on CD4 and MCPyV copy revealed that CD4 counts in
the HIV-1-positive patients were not correlated with
MCPyV copy numbers in the serum (R2 = 0.034, Figure 2).
HPyV6 ST DNA was also detected by real-time PCR in 0
and 2 cases of HIV-1-positive and HIV-1-negative sera, re-
spectively. The two HPyV6 positive HIV-1-negative sera
which were taken from autopsy cases of elder patients
with respiratory failure were negative for MCPyV. HPyV7
was not detected in any serum sample by real-time PCR.
MCPyV, HPyV6, and HPyV7 detection in tissue samples
MCPyV was detected in 22/30 (73%) tissue samples of
MCC, 4/19 (21%) of encephalitis, 3/17 (18%) of pneumo-
nia, 8/14 (57%) of myocarditis, and 0/10 (0%) of hepatitis
by real-time PCR (Table 2). There was no specific histo-
logical difference between MCPyV-positive and negative
cases in each group. Eleven MCPyV-positive samples
of other group in Table 2 were composed of 6 AIDS-
associated Kaposi’s sarcoma, 4 AIDS-associated lymph-
oma, and one AIDS-associated progressive multifocal
leukoencephalopathy cases. Among MCPyV-positive tis-
sues, the mean MCPyV copy number was significantly
higher in the MCC tissues (3.219 copy per cell) than in
the other tissues (0.075 copy per cell, P = 0.0014, Mann-
Whitney U-test, Figure 3). The MCPyV large T antigen
was detectable by immunohistochemistry only in the
MCC samples (Figure 4). One MCPyV-positive MCC
tissue was also positive for HPyV6 ST DNA, but HPyV6
and HPyV7 were not detected in any MCPyV-negativeFigure 1 MCPyV copy number in serum samples from HIV-1+
and HIV-1- patients. MCPyV copy number per μL of serum is
shown. Horizontal and vertical bars indicate the mean and standard
deviation, respectively. The mean MCPyV copy number per μL is
shown in the right of each bar.
Figure 2 MCPyV copies and CD4 count. Each dot plot indicates
MCPyV copy number in the serum and CD4 count per μL of blood
in each HIV-1+ patient. A regression line is shown with regression
coefficient (0.034).
Figure 3 MCPyV copies per cell in tissue samples. The mean
MCPyV copy number per cell is shown in the right of each bar. Error
bars indicate standard error.
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MCPyV-negative MCC and HPyV6 or HPyV7 infection.
One MCC sample and a tissue sample from a Kaposi’s
sarcoma patient were positive for HPyV6 ST DNA by
real-time PCR (Table 2). HPyV7 was not detected in any
tissue sample.
Detection of HPyV6 DNA fragments in nested PCR
We carried out nested PCR analysis on two serum and
two tissue samples which were positive for HPyV6 by
real-time PCR detecting HPyV6 ST DNA. The nested
PCR were able to amplify their targets from ten genome
copies constantly, and did not cross-react with JCV,
BKV, and MCPyV genomes (Figure 5A). Nested PCR
analysis revealed that HPyV6 VP2/3 DNA were failed
to detect in all these cases, whereas a positive control of
HPyV6, a DNA sample extracted from a skin biopsy
which was confirmed to be HPyV6-positive, was positive
for VP2/3 (Figure 5B). HPyV6 LT DNA was negative in
the one serum and one tissue samples, and VP1 was
positive only in one MCPyV-positive MCC case by
nested PCR.Table 2 MCPyV, HPyV6, and HPyV7 detection in tissue
samples by real-time PCR
Disease Organ n MCPyV HPyV6 (ST) HPyV7 (ST, VP1)
MCC skin 30 22 (73.3%) 1 (3.3%) 0 (0%)
Encephalitis brain 19 4 (21.1%) 0 (0%) 0 (0%)
Pneumonia lung 17 3 (17.6%) 0 (0%) 0 (0%)
Myocarditis heart 14 8 (57.1%) 0 (0%) 0 (0%)
Hepatitis liver 10 0 (0%) 0 (0%) 0 (0%)
Other various 60 11 (18.3%) 1 *(1.6%) 0 (0%)
* One HPyV6-positive sample in other group is a Kaposi’s sarcoma tissue.Discussion
In the present study, we detected MCPyV DNA more
frequently in the sera of HIV-1-positive patients than in
the sera of HIV-1-negative patients. Although detailed
characteristics of the HIV-1-positive patients were not
available, we confirmed that these patients were not re-
ceiving antiretroviral therapy and more than half ofFigure 4 Immunohistochemistry for MCPyV in tissue samples.
(A) Hematoxylin and eosin staining of a sample of a patient with
myocarditis positive for MCPyV by real-time PCR. Remarkable
inflammatory cell infiltration is observed in the muscle of the
heart. (B) MCPyV large T antigen cannot be detected by
immunohistochemistry in the inflammatory cells and myocardial
cells. Inset indicates a positive control of Merkel cell carcinoma
which had 0.7 copy per cells of MCPyV by real-time PCR.
Figure 5 Nested PCR and real-time PCR detecting HPyV6-
encoded genes. (A) Sensitivity and specificity of the nested PCR
detecting three HPyV6 gene fragments were confirmed. Sequence-
validated PCR products of HPyV6 were amplified by the nested PCR.
In addition, JCV and BKV-positive controls were examined. (B) Three
HPyV6 gene fragments were detected in tissue and serum samples
positive for HPyV6 by real-time PCR. A case of MCC (lane 1), Kaposi’s
sarcoma (lane 2), and two sera from HIV-1-negative patients (lane 3
and 4) were examined. Average copy numbers of three experiments
for HPyV6 ST and human β-actin genes per 100 ng of DNA (tissue
samples) or DNA extracted from 1 μL of serum were shown in the
bottom. Specific PCR fragments, including large T (LT), VP1, and VP2/
3, were not amplified constantly in lane 1-4. Similar results were
obtained in a repeated experiment. P: positive control of HPyV6, a
DNA sample extracted from a skin biopsy which was confirmed to
be HPyV6-positive, N: no DNA.
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suggesting that the patients were immunocompromised.
Although the correlation between CD4 counts and
MCPyV copies was not shown in the present study
(Figure 2) and the detailed immune status was not deter-
mined in the HIV-1-negative patients, the significantly
different positivity of MCPyV DNA in the serum be-
tween HIV-1-positive and negative patients suggests that
an individual’s immune status is associated with theproduction of MCPyV which will be a crucial factor in
elucidating MCC pathogenesis. It has been reported that
profound immune suppression is one of the important
risk factors for MCC development and that patients with
AIDS have a 13-fold increased risk for MCC compared
with the general population [35]. Thus, a high detection
rate of MCPyV in the serum may be associated with the
clinical incidence of MCC.
MCPyV, HPyV6, and HPyV7 were identified as viruses
shed from the skin [6]. Seroprevalence data from a co-
hort of U.S. patients indicates that these 3 viruses are
common among the general population [6,40]. In con-
trast, our PCR data showed the presence of viral DNA
in less than 10% of serum samples from HIV-1-negative
patients. This finding is consistent with the results by
previous reports describing frequent detection of
MCPyV in the skin samples [6], but rare detection of
MCPyV DNA in blood samples [29]. Considering these
reports and our results, it is suggested that viremia is
rare among infected individuals who are not immuno-
compromised. Although the seroprevalence of the vi-
ruses in Japan is unknown, low detection rates of the
viruses in serum suggest a low titer of circulating virus
or low amounts of viral DNA in the blood of infected in-
dividuals. A low detection rate of viral DNA in MCPyV-
seropositive individuals would suggest that the viruses
are produced in the skin and released from the epithe-
lium, but do not circulate in the blood. Because HPyV6
and HPyV7 were rarely detected even in HIV-1-positive
serum samples, seroprevalence data on these viruses will
be required to interpret the results. In addition, HPyV6
was detected in 4 samples including tissue samples in
the present study, but only 1 MCC tissue was positive
for both VP1 and ST genes. HPyV6 LT DNA was nega-
tive in the one serum and one tissue samples by the
nested PCR among the 4 samples positive for HPyV6 ST
gene by the real-time PCR. Such different reactivities
among polyomavirus-encoded genes in each case were
observed in the previous reports of MCPyV in MCC
[20,22], suggesting sequence mutation in the target
genes or the presence of partial genomes of HPyV6 in
the serum.
MCPyV was detected at a high rate in samples of pa-
tients with myocarditis (57%); additionally, 10–20% of
pneumonia and encephalitis samples were positive. Our
results in the present study showed low copy numbers
of MCPyV in tissues other than MCC. These findings
are constant to previous findings that no or low
amounts of MCPyV was detected in normal tissues or
neoplastic lesions of organs other than the skin [22].
The previous study demonstrated that MCC cases
infected with MCPyV at more than 0.05 copy per cell
were positive in immunohistochemistry for MCPyV
large T antigen [41]. Although more than 0.05 copy per
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myocarditis cases, immunohistochemistry showed no ex-
pression of the MCPyV large T antigen in tissues other
than MCC tissues, indicating no direct association of
MCPyV infection with the pathogenesis of these dis-
eases. However, since MCPyV was detected in inflamma-
tory conditions such as myocarditis and pneumonia by
real-time PCR in the present study, MCPyV production
may be induced by inflammations or inflammatory cyto-
kines. This observation is compatible with a recent find-
ing that inflammatory monocyte is a reservoir for
MCPyV in vivo [42]. Another possibility is that the virus
has an inherent affinity for heart or lung cells. Further
investigation of the virus receptor will be required to de-
termine its affinity.
Conclusions
MCPyV DNA was detected more frequently in the sera
of HIV-1-positive patients than in the sera of HIV-1
-negative patients. HPyV6 was detected in less than 2%
of serum and tissue samples, whereas HPyV7 was not
detected. These results suggest that MCPyV replication
is associated with host immunity, and that circulation of
HPyV6 and HPyV7 in the serum is rare.
Methods
Samples
This study was approved by the institutional review
board at the National Institute of Infectious Diseases
(Approval No. 273). We used 23 HIV-1-positive and
111 HIV-1-negative sera stored at the National Institute
of Infectious Disease. All the HIV-1-positive patients
had not received anti-retrovirus therapy at the time of
blood collection. Their CD4 counts at the time of blood
collection were recorded for analysis. The HIV-1-nega-
tive sera were obtained from patients with variousTable 3 Primer list for HPyV6 nested PCR
Gene Out/In F/R Primer n








HPyV6 VP2/3 Outer Forward HPyV6-VP
Reverse HPyV6-VP
Innner Forward HPyV6-VP
Reverse HPyV6-VPdiseases including influenza virus infection, myocardi-
tis, encephalitis, hepatitis, malignancies, etc. No MCC
patient was included. In addition, formalin-fixed
paraffin-embedded (FFPE) or frozen tissue samples
from 150 patients with various diseases such as enceph-
alitis, pneumonia, myocarditis, and hepatitis were col-
lected. DNA samples extracted from JCV-positive
progressive multifocal leukoencephalopathy and BKV-
associated nephropathy were used as JCV and BKV-
positive controls, respectively.
DNA extraction
DNA was extracted from 50 μL of serum by using the
DNeasy Blood & Tissue Kit (Qiagen GmbH, Hilden,
Germany) according to the manufacturer’s protocol.
DNA from sera was eluted in a final volume of 50 μL of
elution buffer. For tissue samples, DNA was extracted
from three pieces of 10 μm-thick FFPE sections and
10 mg of frozen tissue samples with the Qiaamp FFPE
DNA extraction kit and the DNeasy Tissue Kit (Qiagen),
respectively. DNA from FFPE and frozen tissues were
eluted in a final volume of 30 μL and 100 μL of elution
buffer, respectively.
Real-time PCR
Real-time PCR was performed using a standard TaqManW
PCR kit protocol (Applied Biosystems, Foster City, CA)
on a MX3005P (Stratagene, La Jolla, CA). DNA samples
were analyzed for the presence of MCPyV [22], HPyV6
VP1, HPyV6 small T (ST), HPyV7 VP1, and HPyV7 ST
genes. The amount of human genomic DNA (as measured
by the β-actin gene) in the DNA extracted from each
specimen was also determined. Primers and probes for
HPyV6 and HPyV7 were designed for the VP1 and ST
regions by using Primer Express software (Applied
Biosystems) based on the reference sequences of HPyV6ame 50-30 Product Size
N4088F1 ggagcaggattgggttttct 203 bp
N4290R1 aggccacctccacaatatgg
N4109F2 ttcttaggaggagtgcaaga 149 bp
N4257R2 gaacaatggtgggctgattt
1-1347 F1 ggaggagtggaggttatgga 166 bp
1-1512R1 acagagatgaaccagcatcc
1-1369 F2 cagtgccactttctgaagac 122 bp
1-1490R2 agtgtcggtaaaggtgtagg
23-741 F1 cacttcaactgtggttgcca 187 bp
23-927R1 tccctagaagctgttctctg
23-763 F2 agtttggtcttggggaggcg 138 bp
23-900R2 tccctgcctgctctatagta
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(HM011569). HPyV6-VP1 forward (50-CCCTGGCTGT
TGTTAATTTGC-30) and reverse (50-CTGAAGGCTT
CCCAAACCAA-30) primers were used with the TaqMan
probe 50-(FAM) TGAAATTCCTGAGGCCCTGTGTGA
TGAT (TAMRA)-30. HPyV6-ST forward (50-AAGCA
CCAGGTGGGTGATGA-30) and reverse (50-CAACGCC
TGAATGTTTTAAAGGA-30) primers were used with the
TaqMan probe 50-(FAM) TTGGTCCCTCAGGGTGGC
ATTCAA (BHQ1)-30. HPyV7-VP1 forward (50-AGAAG
GTCCAGGCAATAGTGATG-30) and reverse (50-CTGG
GAAATTTGCAGCATTTACT-30) primers were used
with the TaqMan probe 50-(HEX) AGCTAGCCTGCA
AGCCCTCAGAAAGC (BHQ1)-30. HPyV7-ST forward
(50-CCAGCATTTGCCCCATAAAA-30) and reverse (50-
AAAGCATAAGAAGAAGGCCAAAGA-30) primers were
used with the TaqMan probe 50-(HEX) AGGCCCCCG
GTGGTCTTTAG (BHQ1)-30. Primers and probes for
MCPyV and β-actin were described previously [22]. PCR
amplification was performed in a 20 μL reaction volume
by using QuantiTect Multiplex PCR Master Mix (Qiagen),
with 0.4 μM of each primer, 0.2 μM of TaqMan probe,
and 1 μL of isolated DNA. PCR was carried out at 50°C
for 2 min, 95°C for 15 min, and 40 cycles of 94°C for
1 min and 60°C for 1 min. Quantitative results were
obtained by generating standard curves for sequence-
validated PCR products or plasmids containing HPyV6-
VP1, HPyV6-ST, HPyV7-VP1, HPyV7-ST, MCPyV-LT, or
the cellular target (β-actin gene). Virus copy number per
cell was calculated as previously described, by dividing the
virus copy number by half of the β-actin copy number, be-
cause each cell contains 2 alleles of β-actin [43]. These
real-time PCR amplified at least 10 copies of target gene
constantly, and did not cross-react with JCV and BKV in
JCV or BKV-positive control samples (data not shown). In
addition, HPyV6 and HPyV7 real-time PCR did not amp-
lify any fragment from a plasmid containing a full genome
of MCPyV (data not shown).
Nested PCR
Nested PCR was performed to detect HPyV6 LT, VP1,
and VP2/3 gene. Sequences of outer and inner primers
are listed in Table 3. The first round of amplification
was performed with 100 ng of extracted DNA and high
fidelity Taq DNA polymerase (Roche Diagnostics,
Boehringer Mannheim, Germany) in a final volume of
25 μL. After an initial DNA denaturation for 2 min at
94°C, samples were amplified by 35 cycles of 94°C for
30 sec, 55°C for 30 sec and 72°C for 30 sec, followed by
a final elongation phase of 7 min at 72°C. The second
round was performed with 1 μL of first round PCR
product in a final volume of 25 μL under the following
parameters: 94°C for 30 sec, 55°C for 30 sec, 72°C for
30 sec for 25 cycles, followed by a final elongation phaseof 7 min at 72°C. Five μL of amplification products were
loaded onto agarose gels, electrophoresed, stained with
bromide and visualized under UV light.
Immunohistochemistry
Immunohistochemistry was performed on FFPE samples
with the rabbit anti-MCPyV-LT polyclonal antibody as
the primary antibody, as described previously [41].
Statistical analysis
Data were analyzed using a Chi-square test or Mann-
Whitney U-test on SPSS software (IBM, Armonk, NY).
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